Switzerland· 62141002
Orencia, Injektionslösung zur subkutanen Anwendung (Fertigspritze mit Nadelschutz)
A abatacept product containing abataceptum, registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Abatacept is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AA24 (abatacept), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Abatacept · ATC L04AA24
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abatacept costs, country by country.
Normalised to the WHO defined daily dose (27 mg), so markets compare like for like.
- Switzerland: $59.45 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Abatacept · price per daily dose (27 mg)
USD · FX 28 Sept 2026
- CH Switzerland$59.45
The record
At a glance
Swissmedic (Switzerland)- Active substance
- abataceptum
- Manufacturer
- Bristol-Myers Squibb SA
- Country
- Switzerland (CH)
- ATC code
- L04AA24
- ATC class
- Abatacept
- Defined daily dose
- 27 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806214100254 Fertigspr 1 mlCHF 1044.75
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
63 interactions on record for abatacept.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Abatacept · interactions on record
63 records
- 30 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Abatacept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaORENCIABristol-Myers Squibb Pharma EEIG, Dublin
- FinlandOrenciaBristol-Myers Squibb Pharma EEIG
- BelgiumOrencia 125 mgBristol-Myers Squibb Pharma
- FranceORENCIA 125 mg, solution injectable en seringue préremplieBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomOrencia 125mg/1ml solution for injection pre-filled syringesBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandOrencia 125 mg solution for injection in pre-filled penBristol-Myers Squibb Pharma EEIG
- IcelandOrenciaBristol-Myers Squibb Pharma EEIG*
- SwedenORENCIA 125 mg Injektionsvätska, lösning i förfylld injektionspennaBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Orencia
- Liechtenstein · Orencia
- Norway · Orencia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da6a7d72-d5f7-4cf4-902c-f48625587ad4 GET /v1/drugs/da6a7d72-d5f7-4cf4-902c-f48625587ad4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "abataceptum 125 mg",
"valid_from": "2012-05-01",
"limitations": "[{\"description\":\"Die Behandlung mit Orencia bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes:<br>\\n<br>\\n<b>Rheumatoide Arthritis:</b><br>\\nZur Behandlung der aktiven rheumatoiden Arthritis, wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2020-12-01\"}]",
"galenic_form": "Inj Lös 125 mg/ml mit Nadelschutz",
"therapeutic_area": null,
"sl_inclusion_date": "2012-05-01",
"self_retention_pct": 10
}See everything about abatacept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.